Your browser is no longer supported. Please, upgrade your browser.
Settings
ELDN [NASD]
Eledon Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-10.95 Insider Own9.27% Shs Outstand14.83M Perf Week-6.62%
Market Cap113.36M Forward P/E- EPS next Y-1.45 Insider Trans1.00% Shs Float12.98M Perf Month-8.64%
Income-23.10M PEG- EPS next Q-0.57 Inst Own58.20% Short Float1.34% Perf Quarter-42.32%
Sales- P/S- EPS this Y35.60% Inst Trans45.19% Short Ratio3.35 Perf Half Y-59.80%
Book/sh12.40 P/B0.65 EPS next Y40.80% ROA-15.60% Target Price- Perf Year-13.27%
Cash/sh7.70 P/C1.04 EPS next 5Y- ROE-22.80% 52W Range6.16 - 27.32 Perf YTD-47.79%
Dividend- P/FCF- EPS past 5Y45.40% ROI- 52W High-69.29% Beta1.80
Dividend %- Quick Ratio26.20 Sales past 5Y- Gross Margin- 52W Low36.25% ATR0.72
Employees10 Current Ratio26.20 Sales Q/Q- Oper. Margin- RSI (14)42.90 Volatility8.59% 8.76%
OptionableYes Debt/Eq0.00 EPS Q/Q93.30% Profit Margin- Rel Volume2.23 Prev Close8.04
ShortableYes LT Debt/Eq0.00 EarningsMay 13 AMC Payout- Avg Volume51.85K Price8.39
Recom1.60 SMA20-5.37% SMA50-14.03% SMA200-42.79% Volume40,377 Change4.35%
Mar-23-21Initiated Cantor Fitzgerald Overweight $25
May-18-21 08:00AM  
May-13-21 04:01PM  
02:30PM  
May-05-21 04:01PM  
May-04-21 04:01PM  
Apr-26-21 04:05PM  
Apr-19-21 04:05PM  
Mar-30-21 04:05PM  
02:30PM  
Mar-29-21 02:08AM  
Mar-23-21 08:00AM  
Mar-15-21 08:00AM  
Mar-02-21 08:00AM  
Feb-17-21 08:00AM  
Jan-19-21 05:55PM  
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Little Paul SeanCHIEF FINANCIAL OFFICERJun 11Buy8.8710,00088,70010,000Jun 14 05:24 PM
Gros David-Alexandre CChief Executive OfficerJun 09Buy8.013,00024,0303,000Jun 10 05:25 PM